Cavanaugh Sarah 4
4 · Celldex Therapeutics, Inc. · Filed Aug 19, 2022
Insider Transaction Report
Form 4
Cavanaugh Sarah
SVP OF CORP AFFAIRS & ADMIN.
Transactions
- Exercise/Conversion
Common Stock
2022-08-18$9.02/sh+1,355$12,217→ 2,639 total - Sale
Common Stock
2022-08-17$36.73/sh−31,312$1,150,221→ 1,284 total - Exercise/Conversion
Common Stock
2022-08-17$2.78/sh+31,312$87,047→ 32,596 total - Sale
Common Stock
2022-08-18$36.38/sh−1,355$49,289→ 1,284 total - Exercise/Conversion
Incentive Stock Option
2022-08-17−31,312→ 10,750 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (31,312 underlying) - Exercise/Conversion
Incentive Stock Option
2022-08-18−1,355→ 10,103 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (1,355 underlying)
Footnotes (5)
- [F1]Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- [F5]As of June 13, 2022, the option is fully vested.